Jeffrey W. Ubben
Jeffrey Ubben is a founder, the chief executive officer and the chief investment officer of ValueAct Capital, a San Francisco-based investment partnership with more than $6 billion in assets under management.
View Older Stories View More Recent Stories
-
Form 4 Spivy Gregory P For: Mar 11 Filed by: ValueAct Capital Master Fund, L.P.
-
Valeant's stock rout serves up $5.3 billion in hedge fund losses
-
ValueAct's Jeff Ubben says oil can go to $100 by 2019
-
Allison Transmission (ALSN) Appoints Three Independent Directors; Updates Governance Standards
-
Allison Transmission Announces Corporate Governance Enhancements
-
Form SC 13D/A Motorola Solutions, Inc. Filed by: VA Partners I, LLC
-
VA Partners with PGA to Support PGA HOPE Program for Veterans with Disabilities
-
Form SC 13D/A MSCI Inc. Filed by: VA Partners I, LLC
-
Form 4 MSCI Inc. For: Mar 03 Filed by: VA Partners I, LLC
-
Form 4 MSCI Inc. For: Feb 29 Filed by: ValueAct Capital Management, L.P.
-
Form SC 13D/A Motorola Solutions, Inc. Filed by: VA Partners I, LLC
-
Form SC 13D/A AGRIUM INC Filed by: VA Partners I, LLC
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Form SC 13D/A BAKER HUGHES INC Filed by: VA Partners I, LLC
-
Activist Insight and Schulte Roth & Zabel Release The Activist Investing Annual Review 2016
-
Form 4 ADOBE SYSTEMS INC For: Jan 21 Filed by: ValueAct Capital Management, L.P.
-
UPDATE: American Express (AXP) Taps Session Low; ValuaeAct Said to Liquidate Stake
-
Valeant names interim CEO; timing of Pearson's return unknown
-
Form 4 TWENTY-FIRST CENTURY For: Jan 04 Filed by: UBBEN JEFFREY W
-
Willis Towers Watson (WLTW) Announces Completion of Merger
-
Willis Towers Watson Merger Successfully Completed
-
Valeant selects trio to fill in for ailing CEO; shares dive
-
Valeant Pharma (VRX) Confirms CEO J. Michael Pearson on Medical Leave
-
Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence
-
Form SC 13D/A BAKER HUGHES INC Filed by: VA Partners I, LLC
-
Activist pressure helps reshape U.S. corporates, from Yahoo to Dow
-
Form SC 13D/A MSCI Inc. Filed by: VA Partners I, LLC
-
Microsoft holds annual shareholder meeting
-
Form 4 MSCI Inc. For: Nov 30 Filed by: VA Partners I, LLC
-
Peltz's activist fund Trian to end quarterly redemptions: sources
-
Exclusive: ValueAct gains for the year wiped out by Valeant loss
-
Form 4 MSCI Inc. For: Nov 18 Filed by: ValueAct Capital Master Fund, L.P.
-
Update -- Willis Group and Towers Watson Agree Amended Terms to the Proposed Merger of Equals
-
Willis Group and Towers Watson Agree Amended Terms to the Proposed Merger of Equals
-
Form 4 TWENTY-FIRST CENTURY For: Nov 12 Filed by: UBBEN JEFFREY W
-
ValueAct Capital Management's 13F Shows New Stake in Towers Watson (TW), Fox (FOX), (more...)
-
Valeant Pharma (VRX) on Watch After Larger Holder Frees Up $1B
-
ValueAct Sells 18.65M Microsoft (MSFT) Shares
-
ValueAct Capital Discloses Sale of Shares of Microsoft Corporation.
-
ValueAct Disagrees with ISS Recommendation on Towers Watson (TW) Merger
-
ValueAct Capital Voices Strong Disagreement with ISS Voting Recommendations for Towers Watson Stockholders
-
Form SC 13D/A MSCI Inc. Filed by: VA Partners I, LLC
-
Form SC 13D/A Motorola Solutions, Inc. Filed by: VA Partners I, LLC
-
Form 4 MSCI Inc. For: Nov 05 Filed by: ValueAct Capital Master Fund, L.P.
-
Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying Uncle

